default author photo

Mohamad-Gabriel Alameh

University of Pennsylvania

SCHOLARLY PAPERS

1

DOWNLOADS

119

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Non-Inferiority Phase 2 Immunogenicity and Safety Study of 'Comvigen': A Model for Mrna Vaccine Development in Low- and Middle-Income Countries (LMICs)

Number of pages: 42 Posted: 28 Feb 2025
Chulalongkorn University - Thai Red Cross Emerging Infectious Diseases Clinical Centre, Chulalongkorn University - Center of Excellence in Pediatric Infectious Diseases and Vaccines, Chulalongkorn University - Center of Excellence in Pediatric Infectious Diseases and Vaccines, Thai Red Cross AIDS Research Centre, Bangkok, Chulalongkorn University, Chulalongkorn University, Chulalongkorn University, Armed Forces Research Institute of Medical Sciences, Mahidol University, Chulalongkorn University, National Center for Genetic Engineering and Biotechnology, Chulalongkorn University, Chulalongkorn University, Mahidol University, University of Pennsylvania - Department of Microbiology, University of Pennsylvania, Genevant Sciences Corporation, Genevant Sciences GmbH, BioNet-Asia Co Ltd, Chulalongkorn University and Independent
Downloads 119 (600,462)

Abstract:

Loading...

COVID-19 vaccine booster, Immunogenicity, Safety, Omicron, mRNA vaccine, Pandemic preparedness, Vaccine equity, Neutralizing antibody, T-cells